CellaVision AB Year-end bulletin, Jan-Dec 2018

CellaVision's best quarter ever with strong growth

October 1 - December 31, 2018

·       Net sales increased by 46% to SEK 111,0 million (76.1).

·       Organic growth increased to 44% (6)

·       Operating profit increased to SEK 35.8 million (21.7).

·       The operating margin increased to 32.3% (28.5).

·       Profit before tax increased to SEK 36.0 million (21.7).

·       Earnings per share increased to SEK 1.24 (0.73). 

·       Cash flow for operating activities amounted to SEK 12.8 million (28.9).

January 1 - December 31, 2018

·       Net sales increased by 18% to SEK 364.8 million (309.3).

·       Organic growth was 15% (16).

·       Operating profit increased to SEK 111.6 million (90.9).

·       The operating margin increased to 30.6% (29.4).

·       Profit before tax increased to SEK 112.1 million (90.3).

·       Earnings per share increased to SEK 3.72 (2.92).

·       Cash flow for operating activities amounted to SEK 74.1 million (87.9). 

·       The Board of Directors proposes a dividend of 1.50 SEK per share in 2018 (SEK 1.50).

 

Significant events after period close

·       The CellaVision DC-1, for small and mid-sized laboratories, received CE-marking in February 2019 and is now commercially available. 

CEO's comments 

Fourth quarter - CellaVision's best quarter ever
The fourth quarter of 2018 was CellaVision's best quarter ever after strong growth in all regions and sales that for the first time in an individual quarter exceeded SEK 100 million. Sales were SEK 111 million (76.1), corresponding to organic growth of 44 percent. Profitability progressed well during the quarter, with an operating profit of SEK 35.8 million (21.7), corresponding to an operating margin of 32.3 percent (28.5). The profitability trend is a result of CellaVision's effective indirect sales model that enables ambitious geographical expansion with continued sound cost control. Exchange rate impact was low in the quarter, about two percent.